Progressive Supranuclear Palsy Treatment Market By Drug Type (Dopamine, Anticholinergic Agents, Tricyclic Antidepressants, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region - Market Trends, Analysis, and Forecast till 2029

Progressive Supranuclear Palsy Treatment market accounted for USD 51.1 Billion in 2020 and is estimated to be USD 24.0 Billion by 2029 and is anticipated to register a CAGR of 5.3%.

Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.

Impact of Covid-19 pandemic on market

With the outbreak of the COVID-19, various businesses are at the forefront to combat this pandemic. The pandemic has hindered the industrial supply chain and also disrupted the product segment. Government across the countries has imposed strict lockdown to limit the spread of disease. COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in Application, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of such drugs from one place to another. Moreover the COVID-19 pandemic has impacted the supply of raw materials and potent compounds, which are used for manufacturing drugs such as Progressive Supranuclear Palsy Treatment and this is expected to hamper the market growth in the near future. This report will quantify the impact of a pandemic on the progressive supranuclear palsy treatment market.

Rising incidences of progressive Supranuclear palsy

The rising incidences of progressive Supranuclear palsy worldwide are a key factor aiding in expansion of the progressive Supranuclear palsy treatment market. Progressive Supranuclear palsy paralysis, also known as Steele-Richardson-Olszewski condition, is an unprecedented mind issue that causes major issues with strolling, equilibrium and eye developments. The problem results from disintegration of cells in zones of your cerebrum that control body development and thinking. Reformist supranuclear paralysis deteriorates over the long haul and can prompt perilous difficulties, like, pneumonia and gulping issues. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in July 2020, reports that globally the prevalence of progressive supranuclear palsy is 5.8 to 6.5 per 100,000 persons, and the annual incidence rate ranges from 0.3 to 0.4 per 100,000 persons.

Increasing focus on research and development

The major market players are actively focusing on research and development for progressive supranuclear palsy treatment for cost effective and quality treatment. For instance, in July 2018, Asceneuron, a Switzerland-based biotechnology company received orphan drug designation, for its lead drug ASN120290 from the U.S. Food and Drug Administration (FDA). ASN120290’s therapeutic potential has been demonstrated in pre-clinical studies, indicated for the treatment of rare neurodegenerative disease, progressive supranuclear palsy (PSP). However, the lack of knowledge and inadequate research and development for treatment is expected to hinder the market growth. The ongoing clinical trials are lacking in identification of disease-modifying therapies often targeting the underlying tau pathology.

The progressive supranuclear palsy treatment market is segmented based on drug type, distribution channel, and region.

On the basis of drug type, the progressive supranuclear palsy treatment market is segmented into dopamine, anticholinergic agents, tricyclic antidepressants, and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Regional Insights:

On region the progressive supranuclear palsy treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America progressive supranuclear palsy (PSP) market has been growing at a tremendous pace in recent times. The presence of a seamless sector for neural research in the US and Canada has created new avenues for market growth across the region. Besides, the presence of state-of-the-art technologies for brain cell study in the region has also aided market expansion.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the progressive supranuclear palsy treatment market report based on drug type, distribution channel, and region.

Progressive Supranuclear Palsy Treatment Market, By Drug Type:

• Dopamine
• Anticholinergic Agents
• Tricyclic Antidepressants
• Others

Progressive Supranuclear Palsy Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Progressive Supranuclear Palsy Treatment Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • U.S.
  • Canada

The key players operating in the progressive supranuclear palsy treatment market includes AbbVie Inc., Acorda Therapeutics Inc., Biogen Inc., Bristol-Myers Squibb Co., Merck & Co. Inc., UCB Biopharma, AlzProtect, Asceneuron Therapeutics, TauRx Pharmaceuticals, GlaxoSmithKline PLC, Novartis AG, and Teva Pharmaceutical Industries Ltd. The market is especially characterized by collaborations and partnerships between the businesses and acquisitions of smaller players as a part of strategic expansion as well as launching their new product specimen. For instance, In September 2019, UCB S.A., a biopharmaceutical company based in Belgium focusing on the discovery and development of innovative medicines and solutions, released a new data for UCB0107, an anti-Tau immunotherapy Phase I study results at World Movement Disorders Conference, France. UCB0107 is a recombinant, humanized, full-length IgG4 monoclonal antibody, a potential treatment for patients with progressive supranuclear palsy (PSP).

• AbbVie Inc.
• Acorda Therapeutics Inc.
• Biogen Inc.
• Bristol-Myers Squibb Co.
• Merck & Co. Inc.
• UCB Biopharma
• AlzProtect
• Asceneuron Therapeutics
• TauRx Pharmaceuticals
• GlaxoSmithKline PLC
• Novartis AG
• Teva Pharmaceutical Industries Ltd.